With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

Small cell ther­a­py com­pa­ny Ido­gen will have to liq­ui­date the com­pa­ny if an­oth­er so­lu­tion isn’t found soon, like a re­verse merg­er or the sale of its plat­form, as its cash dwin­dles.

On Tues­day, Swe­den-list­ed Ido­gen (STO: $IDO­GEN) said it had start­ed con­ver­sa­tions around a re­verse merg­er — but there isn’t much time, as a pro­pos­al for liq­ui­da­tion will be dis­cussed at its an­nu­al gen­er­al meet­ing on June 8. Ido­gen added that un­less its tech­nol­o­gy plat­form is sold and “yields the de­sired re­sult,” share­hold­ers can’t count on any fi­nan­cial gain in the case of liq­ui­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER